Cited by 188Sirtuins and Resveratrol in MedicineLiver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study

Open access

Faghihzadeh, Forouzan, Adibi, Payman, Hekmatdoost, Azita·2015·British Journal Of Nutrition

DOI 10.1017/s0007114515002433

Open this paper in CoChat — free account Open PDF

Abstract

Non-alcoholic fatty liver disease (NAFLD) is usually associated with insulin resistance, central obesity, reduced glucose tolerance, type 2 diabetes mellitus and hypertriacylglycerolaemia. The beneficial effects of resveratrol on metabolic disorders have been shown previously. The aim of this study was to evaluate the effects of resveratrol supplementation on cardiovascular risk factors in patients with NAFLD. In this randomised double-blinded placebo-controlled clinical trial, fifty NAFLD patients were supplemented with either a 500-mg resveratrol capsule or a placebo capsule for 12 weeks. Both groups were advised to follow an energy-balanced diet and physical activity recommendations. resveratrol supplementation reduced alanine aminotransferase (ALT) and hepatic steatosis significantly more than placebo (P0·05). There were no significant changes in blood pressure, insulin resistance markers and TAG in either group (P>0·05). Our data have shown that 12-week supplementation of 500 mg resveratrol does not have any beneficial effect on anthropometric measurements, insulin resistance markers, lipid profile and blood pressure; however, it reduced ALT and hepatic steatosis in patients with NAFLD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1017/s0007114515002433

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Compendium of physical activities: an update of activity codes and MET intensities
AINSWORTH, B. E., HASKELL, W. L., WHITT, M. C., IRWIN, M. L., SWARTZ, A. M., STRATH, S. J., O???BRIEN, W. L., BASSETT, D. R., SCHMITZ, K. H., EMPLAINCOURT, P. O., et al. (2000) · Medicine & Science in Sports & Exercise · doi:10.1097/00005768-200009001-00009 · Cited by 8,497
Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans
Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H., van de Weijer, T., Goossens, G. H., Hoeks, J., van der Krieken, S., Ryu, D., Kersten, S., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.10.002 · Cited by 1,320
Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients
Brasnyó, P., Molnár, G. A., Mohás, M., Markó, L., Laczy, B., Cseh, J., Mikolás, E., Szijártó, I. A., Mérei, Á., Halmai, R., et al. (2011) · British Journal Of Nutrition · doi:10.1017/s0007114511000316 · Cited by 680
Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus
Bhatt, J. K., Thomas, S., & Nanjan, M. J. (2012) · Nutrition Research · doi:10.1016/j.nutres.2012.06.003 · Cited by 475
High-Dose Resveratrol Supplementation in Obese Men
Poulsen, M. M., Vestergaard, P. F., Clasen, B. F., Radko, Y., Christensen, L. P., Stødkilde-Jørgensen, H., Møller, N., Jessen, N., Pedersen, S. B., & Jørgensen, J. O. L. (2013) · Diabetes · doi:10.2337/db12-0975 · Cited by 455
Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study
Eslamparast, T., Poustchi, H., Zamani, F., Sharafkhah, M., Malekzadeh, R., & Hekmatdoost, A. (2014) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.068890 · Cited by 412
Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats
Rivera, L., Morón, R., Zarzuelo, A., & Galisteo, M. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.11.027 · Cited by 391
Resveratrol Supplementation Does Not Improve Metabolic Function in Nonobese Women with Normal Glucose Tolerance
Yoshino, J., Conte, C., Fontana, L., Mittendorfer, B., Imai, S., Schechtman, K. B., Gu, C. C., Kunz, I., Fanelli, F. R., Patterson, B. W., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.09.015 · Cited by 389
GI Epidemiology: nonalcoholic fatty liver disease
Angulo, P. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03246.x · Cited by 370
Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity
Qiao, Y., Sun, J., Xia, S., Tang, X., Shi, Y., & Le, G. (2014) · Food & Function · doi:10.1039/c3fo60630a · Cited by 367

Show all 35 references

Sorted by citations

Items 101–187 of 187

Natural Products from Mediterranean Diet: From Anti-hyperlipidemic Agents to Dietary Epigenetic Modulators
Deligiannidou, G.-E., Athina, S., Berghe, W. V., Christos, K., & Constantinides, T. K. (2019) · Current Pharmaceutical Biotechnology · doi:10.2174/1573407215666190628150921 · Cited by 17
Flavonoids and Their Role in Preventing the Development and Progression of MAFLD by Modifying the Microbiota
Sokal-Dembowska, A., Jarmakiewicz-Czaja, S., & Filip, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011187 · Cited by 16
“Nevertheless, there are also data from clinical trials that do not support the efficacy of RSV supplementation in the treatment of MAFLD [94–100].”
Result
Hepatocellular Interactions of Potential Nutraceuticals in the Management of Inflammatory NAFLD
Ezhilarasan, D., & Kulanthaivel, L. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4112 · Cited by 17
A Comparison of the Effectiveness of Silibinin and Resveratrol in Preventing Alpha‐Amanitin‐Induced Hepatotoxicity
Şahin, A., Arıcı, A., Yılmaz, Y., Kalkan, Ş., Durmuş, N., Ergür, B. U., Aksu, İ., Atabey, N., & Tunçok, Y. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12954 · Cited by 16
Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver Disease
Ciobârcă, D., Cătoi, A. F., Gavrilaș, L., Banc, R., Miere, D., & Filip, L. A. (2025) · Pharmaceuticals · doi:10.3390/ph18020279 · Cited by 18
S2k-Leitlinie Klinische Ernährung in der Hepatologie
Plauth, M., Bechmann, L. P., Grajecki, D., Gundling, F., Kramer, L., Kremer, A. E., Rau, M., Schneider, A., Tacke, F., & van Thiel, I. (2024) · Aktuelle Ernährungsmedizin · doi:10.1055/a-2338-1144 · Cited by 14
Stilbenoids: Chemistry, occurrence, bioavailability and health effects—a review
Oh, W. Y., Gao, Y., & Shahidi, F. (2021) · Journal of Food Bioactives · doi:10.31665/jfb.2020.13256 · Cited by 16
“However, it improved alanine aminotransferase (ALT) and hepatic steatosis, which are indicators of liver health (Faghihzadeh et al., 2015).”
Background
Evaluating Bioactive-Substance-Based Interventions for Adults with MASLD: Results from a Systematic Scoping Review
Handu, D., Stote, K. S., & Piemonte, T. A. (2025) · Nutrients · doi:10.3390/nu17030453 · Cited by 12
“…124,128,132,134–136,138,140], overweight (n = 31) [12,23,24,26,28–30, 36, While individuals with MASLD (n = 124) [10–25,27–29,31–35,37–61,63–85,87–103,105–140] and MASH (n = 7) [26,30,36,62,86,104] were the…”
Pharmacologic Treatment of Polycystic Ovary Syndrome: Alternate and Future Paths
Legro, R. S., & Martel‐Duguech, L. (2017) · Seminars in Reproductive Medicine · doi:10.1055/s-0037-1603729 · Cited by 11
Alcoholic and Non-Alcoholic Liver Diseases: Promising Molecular Drug Targets and their Clinical Development
Thapa, K., Grewal, A. S., Kanojia, N., Rani, L., Sharma, N., & Singh, S. (2020) · Current Drug Discovery Technologies · doi:10.2174/1570163817666200121143959 · Cited by 12
Effects of different natural products in patients with non‐alcoholic fatty liver disease—A network meta‐analysis of randomized controlled trials
Liu, H., Li, Y., Yan, J., Li, X., Wang, D., Yu, X., Jiang, Z., Yin, G., Chen, S., Zhang, X., et al. (2024) · Phytotherapy Research · doi:10.1002/ptr.8182 · Cited by 11
“…variable (Anushiravani et al., 2019; Asghari et al., 2018; Chachay et al., 2014; Chashmniam et al., 2019; Chen et al., 2015; Cicero et al., 2020; Faghihzadeh et al., 2015; Heebøll et al., 2016; Jarhahzadeh et al., 2021; Jazayeri-Tehrani et al., 2019; Kantartzis et al., 2018; Mirhafez et…”
Influential
Efficacy of dietary polyphenol supplement in patients with non-alcoholic fatty liver disease: a network meta-analysis
Wang, X., Li, S., & Wang, X.-H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1582861 · Cited by 13
Polyphenol intakes and risk of impaired lipid profile, elevated hepatic enzymes and nonalcoholic fatty liver disease
Nikkhah‐Bodaghi, M., Ghanavati, M., & Hekmatdoost, A. (2019) · Nutrition & Food Science · doi:10.1108/nfs-12-2018-0338 · Cited by 11
The effect of resveratrol supplementation on biomarkers of liver health: A systematic review and meta‐analysis of randomized controlled trials
Soltani, S., Sharifi‐Zahabi, E., Sangsefidi‬, Z. S., Vasmehjani, A. A., Meshkini, F., Clayton, Z. S., & Abdollahi, S. (2023) · Phytotherapy Research · doi:10.1002/ptr.7719 · Cited by 11
The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment
Zhou, J., Chen, Y., Yu, J., Li, T., Lu, Z., Chen, Y., Zhang, X., & Ye, F. (2021) · Medicine · doi:10.1097/md.0000000000024884 · Cited by 11
Bioactive Compounds for the Management of Hypertriglyceridemia: Evidence From Clinical Trials and Putative Action Targets
Schiano, E., Annunziata, G., Ciampaglia, R., Iannuzzo, F., Maisto, M., Tenore, G. C., & Novellino, E. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.586178 · Cited by 10
Effects of resveratrol supplementation on liver enzymes: A systematic review and meta‐analysis of randomised controlled trials
Darand, M., Farrokhzad, A., Ghavami, A., Hadi, A., Karimi, E., Fadel, A., & Askari, G. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13692 · Cited by 10
Administration of Low-dose Resveratrol Attenuated Hepatic Inflammation and Lipid Accumulation in High Cholesterol-fructose Diet-induced Rat Model of Nonalcoholic Fatty Liver Disease
Chang, C., Chang, C.-Y., Lin, P.-C., Huang, J., Chen, K., Yen, T., & Hung, L. (2020) · The Chinese Journal of Physiology · doi:10.4103/cjp.cjp_43_20 · Cited by 10
A Cross-Sectional Study on Anti Hepatitis B Immune Status in Vaccinated Healthcare Workers in the West Pomeranian Region of Poland
Gańczak, M. (2012) · Hepatitis Monthly · doi:10.5812/hepatmon.5125 · Cited by 10
Nigella sativa and Non-Alcoholic Fatty Liver Disease: A Review of the Current Evidence
Darand, M., Alavian, S. M., & Hekmatdoost, A. (2018) · Hepatitis Monthly · doi:10.5812/hepatmon.68046 · Cited by 9
CALISTHENICS EXERCISES TO INTERVENE IN OBESITY AND DIABETES IN MIDDLE-AGED PEOPLE
Kong, N., Yang, G., Wang, L., & Li, Y. (2022) · Revista Brasileira de Medicina do Esporte · doi:10.1590/1517-8692202228022021_0457 · Cited by 9
Herbs to treat liver diseases: More than placebo?
Stickel, F., & Hellerbrand, C. (2015) · Clinical Liver Disease · doi:10.1002/cld.515 · Cited by 9
“No beneficial effects on anthropometric measurements, insulin resistance markers, lipid profile, and blood pressure were found, but resveratrol reduced ALT and hepatic steatosis significantly more than placebo.(14) Further rigorously designed trials with clear endpoints are needed to assess the efficacy of resveratrol…”
Background
Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis
Komolafe, O., Buzzetti, E., Linden, A., Best, L. M., Madden, A. M., Roberts, D., Chase, T. J., Fritche, D., Freeman, S. C., Cooper, N. J., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013157.pub2 · Cited by 21
Resveratrol Effects on Metabolic Syndrome Features: A Systematic Review and Meta-Analysis
Batista-Jorge, G. C., Barcala-Jorge, A. S., Lelis, D. D. F., Santos, D. E. O., Jorge, A. H. B., Monteiro-Júnior, R. S., & Santos, S. H. S. (2024) · Endocrines · doi:10.3390/endocrines5020016 · Cited by 10
“[9,19,23,25,33,35,37– 40, 42– 44,”
Background
Crosstalk Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Atrial Fibrillation: Shared Mechanism, Diagnostic Integration, and Management Implications
Morawska, A., Frankowski, R., Grabarczyk, M., Kosmalski, M., & Różycka-Kosmalska, M. (2025) · Life · doi:10.3390/life15111713 · Cited by 11
Network pharmacology and molecular docking study on the effect of Kaempferol in treatment of metabolic associated fatty liver disease.
Zhou, K., Zhang, D., Bao, H., & Lijing, L. (2022) · PubMed Central · doi:10.19852/j.cnki.jtcm.20220815.003 · Cited by 8
Galactose intake is related to nonalcoholic fatty liver disease
Emamat, H., Farhadnejad, H., Poustchi, H., & Hekmatdoost, A. (2018) · Nutrition & Food Science · doi:10.1108/nfs-06-2018-0174 · Cited by 8
The clinical value of serum sirtuin-1 concentration in the diagnosis of metabolic dysfunction-associated steatotic liver disease
Amirkhizi, F., Taghizadeh, M., Khalese-Ranjbar, B., Shahraki, S. H., & Asghari, S. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03613-8 · Cited by 7
Impact of flaxseed supplementation on lipid profile and liver enzymes in patients with non-alcoholic fatty liver disease: Systematic review and meta-analysis of randomized controlled trials
Ahmed, D. H., & Fateh, H. L. (2024) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2024.106838 · Cited by 7
Bioactive compounds and inflammation: an overview
Corsi, G. C., Yoshime, L. T., Corrêa, T. A. F., & Rogero, M. M. (2020) · Nutrire · doi:10.1186/s41110-020-00118-0 · Cited by 7
Effects of Resveratrol Supplementation on Nonalcoholic Fatty Liver Disease Management
Nemati, A., Nikniaz, Z., & Mota, A. (2023) · Topics in Clinical Nutrition · doi:10.1097/tin.0000000000000314 · Cited by 5
Functional Foods for Type 2 Diabetes
Hamasaki, H. (2016) · AIMS Medical Science · doi:10.3934/medsci.2016.3.278 · Cited by 5
Effects of polyphenol supplementation on hepatic steatosis, intima-media thickness and non-invasive vascular elastography in obese adolescents: a pilot study protocol
Moretti, J.-B., Drouin, A., Truong, C., Youn, E. Y., Cloutier, A., Álvarez, F., Paganelli, M., Grzywacz, K., Jantchou, P., Dubois, J., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-074882 · Cited by 5
“41 42 A systematic review of resveratrol (a polyphenol) in adults demonstrated inconclusive effects on NAFLD.”
Background
What are the main areas of focus to prevent or treat non‐alcoholic fatty liver disease?
Mansour, A., Hekmatdoost, A., & Mirmiran, P. (2019) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12751 · Cited by 5
Resveratrol impacts health in patients with diabetes mellitus and other metabolic conditions
Nowak, E., Psiuk, D., Rocka, A. A., Dycha, N., Jasielski, P. P., Jasielska, F., Madras, D. K., & Rocka, E. (2022) · Journal of Education Health and Sport · doi:10.12775/jehs.2022.12.11.045 · Cited by 4
Targeting cAMP signaling and phosphodiesterase 4 for liver disease treatment
Ma, J., Staller, D. W., & Mahato, R. I. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03267-3 · Cited by 6
“In another study, the resveratrol supplement did not mitigate oxidative stress or cardiovascular risk factors in patients with MAFLD [104, 105].”
Resveratrol: A Narrative Review Regarding Its Mechanisms in Mitigating Obesity‐Associated Metabolic Disorders
Cai, Y., & Chen, Q. (2024) · Phytotherapy Research · doi:10.1002/ptr.8416 · Cited by 4
Prevention of Nonalcoholic Fatty Liver Disease (NAFLD) Progression to Nonalcoholic Steatohepatitis (NASH) by Modification of Lifestyle and Dietary Supplements
Hekmatdoost, A. (2016) · Journal of Clinical Nutrition & Dietetics · doi:10.4172/2472-1921.100015 · Cited by 4
Blond and blood juice supplementation in high fat diet fed mice: effect on antioxidant status and DDAH/ADMA pathway
Sorrenti, V., Giacomo, C. D., Acquaviva, R., Cosenza, J., Carota, G., & Galvano, F. (2019) · RSC Advances · doi:10.1039/c9ra00669a · Cited by 4
Resveratrol supplementation and flow-mediated dilation: a systematic review
Emamat, H., Djafarian, K., Tangestani, H., Hekmatdoost, A., & Shab‐Bidar, S. (2018) · Nutrition & Food Science · doi:10.1108/nfs-08-2018-0245 · Cited by 4
Senotherapeutics: Milestones, innovations, and future prospects
Atasever, E., Atayik, M. C., & Çakatay, U. (2025) · Advances in pharmacology · doi:10.1016/bs.apha.2025.01.021 · Cited by 3
CARDIOVASCULAR CHANGE IN ATHLETES AT DIFFERENT TRAINING STATUS LEVELS
Zhang, X. (2022) · Revista Brasileira de Medicina do Esporte · doi:10.1590/1517-8692202228012021_0456 · Cited by 3
The effect of natural products use on blood pressure in Iran: Systematic review and meta-analysis
Fakhri, M., Fatahian, A., Yousefi, S. S., Moosazadeh, M., & Azadbakht, M. (2022) · Journal of Nursing and Midwifery Sciences · doi:10.4103/jnms.jnms_74_21 · Cited by 3
Effects of polyphenols on human health
Belojević, G. (2023) · Galenika Medical Journal · doi:10.5937/galmed2307046b · Cited by 3
Dietary Interventions in Fatty Liver
Yari, Z., & Hekmatdoost, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814468-8.00020-x · Cited by 3
Hepatic Biomarkers in Diabetes as Modulated by Dietary Phytochemicals
Basu, A., Basu, P., & Lyons, T. J. (2017) · Biomarkers in disease · doi:10.1007/978-94-007-7675-3_35 · Cited by 3
Nutraceuticals for Non-alcoholic Fatty Liver Disease
Sonmez, A., Ercin, C., Cesur, M., & Doğru, T. (2021) · Contemporary cardiology · doi:10.1007/978-3-030-62632-7_9 · Cited by 2
Herbal treatments for non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials
Rathnayake, D. W., Sooriyaarachchi, P., Niriella, M. A., Ediriweera, D. S., & Perera, J. A. (2024) · Advances in Integrative Medicine · doi:10.1016/j.aimed.2024.08.016 · Cited by 2
Effects of a novel weight-loss combination product containing orlistat and resveratrol on obesity: A multicenter randomized controlled study (EC-FIT)
Win, K. M., Latt, T. S., Bwa, A. H., Aye, K. M., Tun, K. S., & Gandhi, H. (2025) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2025.100218 · Cited by 2
Resveratrol
Krstonošić, M. A., Mikulić, M., & Cvejić, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822923-1.00026-1 · Cited by 3
Effects of 8 weeks of aerobic training and resveratrol on physical fitness, insulin resistance, liver function, and blood pressure in T2DM elderly women
Choi, H.-J., Lee, M.-G., & Kim, Y. Y. (2016) · Korean Journal of Sport Science · doi:10.24985/kjss.2016.27.3.507 · Cited by 2
Las Cortes Españolas en el régimen de Franco: nacimiento, desarrollo y extinción de una Cámara Orgánica
Martínez, G., & Ángel, M. (2012) · Congreso de los Diputados eBooks · Cited by 2
Role of natural products as therapeutic option against nonalcoholic fatty liver disease
Bhat, A. M., Sharma, R. R., & Tasduq, S. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90572-5.00029-9 · Cited by 2
Effects of Resveratrol on Liver Function Tests in Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trials
Ebrahimpour, P., Karamian, M., & Sharifi, A. (2024) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2024-34-1-37-46 · Cited by 1
Efficacy of selected dietary supplements and pharmacological agents on metabolic and oxidative stress outcomes in metabolic dysfunction–associated fatty liver disease (MAFLD): a Bayesian network meta-analysis
Yang, Y., He, X., Cai, J., Qu, X., Tan, S., You, J., He, Y., Yao, Z., & Yang, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1682688 · Cited by 1
Hepatic Biomarkers in Diabetes as Modulated by Dietary Phytochemicals
Basu, A., Basu, P., & Lyons, T. J. (2016) · Exposure and Health · doi:10.1007/978-94-007-7742-2_35-1 · Cited by 1
Plant Polyphenols in Obesity and Obesity-Associated Metabolic Disorders: A Narrative Review of Resveratrol and Flavonoids Upon the Molecular Basis of Inflammation
Bueno, A. A. (2018) · Journal of Obesity and Nutritional Disorders · doi:10.29011/2577-2244.100029 · Cited by 1
Nutrition in liver disease
Plauth, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98368-6.00004-5 · Cited by 1
Os efeitos dos nutracêuticos no tratamento da doença hepática gordurosa não alcoólica: uma revisão integrativa
de Oliveira, A. C., Viana, K. K. G., Lima, A. T. A., Martinho, S. I. D. S., & de Oliveira, D. R. (2020) · Research Society and Development · doi:10.33448/rsd-v9i8.5866 · Cited by 1
Resveratrolün Kardiyovasküler Hastalıklar Üzerine Etkileri
Çıracı, E., & Kalafat, T. (2021) · Journal of Nutrition and Dietetics · doi:10.33076/2021.bdd.1362 · Cited by 7
Research on FAGP Alarm System Based on Multi-Temperature Sensor
Zhao, J. C. (2019) · International Conference on Measuring Technology and Mechatronics Automation (ICMTMA) · doi:10.1109/icmtma.2019.00073
Non alcoholic fatty liver disease: pathogenesis, role of (TNF-α, IL-6) in hepatic inflammation and future potential nutraceutical treatment
Faheem, S. A., Saeed, N. M., El‐Naga, R. N., & Azab, S. S. (2019) · Archives of Pharmaceutical Sciences Ain Shams University · doi:10.21608/aps.2019.17201.1012
“Moreover, It reduces the level of ALT, steatosis and finally HOMA-IR in patients with NAFLD [94].”
Background
Hepatoprotective activity of natural compounds and plant extracts in nonalcoholic fatty liver disease
Sureda, A., Capó, X., & Tejada, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816488-4.00007-3
The European Society for Clinical Nutrition and Metabolism practical guideline: Clinical nutrition in liver disease
Bischoff, S. C., Bernal, W. E., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., Plauth, M., Скрипник, І. М., & Shvets, O. (2021) · Modern Gastroenterology · doi:10.30978/mg-2021-1-59
Polyphenols and their effects on metabolic syndromes and other CVD risk factors
Duttaroy, A. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822405-2.00001-3
Alkole Bağlı Olmayan Yağlı Karaciğer Hastalığı Tedavisinde Bazı Antioksidanların Rolü
Göncü, G., & Kargar, A. (2022) · Journal of Nutrition and Dietetics · doi:10.33076/2022.bdd.1555
“12 haftalık 500 mg resveratrol takviyesinin, NAYKH görülen 50 hastada ALT düzeyi ve hepatik steatozu plaseboya kıyasla daha fazla azalttığı gözlenmiştir (34).”
The effect of 8 weeks of aerobic training and resveratrol consumption on the indicators of metabolic syndrome in overweight women
Hosseini, M., & Dorani, S. E. (2021) · Journal of Sports Physiology and Athletic Conditioning · doi:10.61186/jspac.19967.1.2.31
Besin Takviyelerine Bilimsel Bakış
Fidancı, A., Akpınar, B., Kutsal, E., Bal, E., Yıldırım, E., Duman, E. U., Ergin, E., Paksoy, F. N., Derici, G. E., Ergene, G., et al. (2022) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.1062
Additional file 4 of A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521104
Additional file 1 of A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521095
Additional file 3 of A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521101
Additional file 5 of A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521107
Additional file 7 of A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521113
Additional file 12 of A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521092
Additional file 2 of A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521098
Additional file 11 of A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521089
Additional file 6 of A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521110
Additional file 1 of Protective effect of resveratrol on mitochondrial biogenesis during hyperoxia-induced brain injury in neonatal pups
Yang, M., Shen, Y., Zhao, S., Zhang, R., Dong, W., & Lei, X. (2023) · Figshare · doi:10.6084/m9.figshare.22697034
Natural Products as Promising Drug Candidates for Management of Lifestyle Diseases
Sakr, H. F., & Sirasanagandla, S. R. (2025) · Springer eBooks · doi:10.1007/978-981-95-0575-3_25
Foods, herbs, and phytoconstituents in alleviating metabolic dysfunction-associated fatty liver disease: A review
Neelab, Zeb, A., & Jamil, M. (2026) · Journal of Agriculture and Food Research · doi:10.1016/j.jafr.2026.102648
Neutrophil extracellular Trap-related genes in NAFLD: Biomarkers and therapeutic targets
Rao, H., Chen, J., Chen, Y., & Jiang, J. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02139-x
Enhancing the Anticancer Efficacy of Polyphenols Through Lipid‐Based and Polymeric Nanoparticle Delivery Systems in Triple‐Negative Breast Cancer (TNBC)
Goudarzi, N., Bahadoran, E., Alaei, M., Taebi, K., Ashrafzadeh, A., Shahbaz, A. K., & Shahbaz, S. K. (2026) · Journal of Chemistry · doi:10.1155/joch/3870015
Translating Resveratrol Research: A Systematic Review on Patents and Clinical Trials (2000–2025)
Kaurav, M., Ghai, R., Pal, N., & Nagarajan, K. (2026) · The Open Biotechnology Journal · doi:10.2174/0118740707407791260409045456
High-fat diet, gut dysbiosis, and oxidative stress: A synergistic triangle in metabolic dysfunction-associated steatotic liver disease pathogenesis
Zhang, Z.-R., She, L., Cao, Y., & Chen, Y.-W. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i4.116074
No beneficial effect of resveratrol supplementation on plasma apolipoprotein B and apolipoprotein A-I levels: a systematic review and meta-analysis of randomized controlled trials
Simental‐Mendía, L. E., Arce‐Quiñones, M., & Sahebkar, A. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104866
Effects of Resveratrol Supplementation on Metabolic and Anthropometric Outcomes in Non-Alcoholic Fatty Liver Disease: An Umbrella Review and Updated Meta-Analysis
Molani‐Gol, R., Ebrahimi, A., Safari, S., & Rafraf, M. (2026) · International Journal for Vitamin and Nutrition Research · doi:10.31083/ijvnr48116
Efficacy of plant extracts for metabolic dysfunction-associated steatotic liver disease: a network meta-analysis
Xie, Z., & Chen, T. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1919204
“…Ferro et al., 2020; Han et al., 2020; Maurotti et al., 2024; Hosseinab et al., 2019; Ferro et al., 2022; Milkarizi et al., 2024; Parsi et al., 2020; Faghihzadeh et al., 2015; Hong et al., 2021; Jafa et al., 2023; Zamani et al., 2018; Izadi et al., 2021; Jinato et al., 2022; Lewis et al., 2018;…”

Authors: Faghihzadeh, F., Adibi, P., & Hekmatdoost, A.
Affiliations: National Nutrition and Food Technology Research Institute (IR)
Corresponding author: Hekmatdoost, Azita
ORCID: Hekmatdoost, Azita
Venue: British Journal Of Nutrition
Publisher: Cambridge University Press (CUP)
Published: 2015-08-03
Volume: 114
Issue: 5
Pages: 796-803
ISSN: 0007-1145 (ISSN-L)
1475-2662
DOI: 10.1017/s0007114515002433
OpenAlex: W2246929884
Cited by: 188
References: 35
Citations by year: 2026: 9 · 2025: 9 · 2024: 17 · 2023: 13 · 2022: 28 · 2021: 18 · 2020: 17 · 2019: 15 · 2018: 20 · 2017: 12 · 2016: 25 · 2015: 2
FWCI: 9.94
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.cambridge.org/core/terms (unspecified)
Locations: British Journal Of Nutrition (publishedVersion)
PubMed (publishedVersion)
Funders: National Science Foundation
Iran National Science Foundation
National Nutrition and Food Technology Research Institute
Topics: Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords: resveratrol, non-alcoholic fatty liver disease, cardiovascular risk factors, insulin resistance, alanine aminotransferase, hepatic steatosis, lipid profile, blood pressure, hypertriglyceridemia, dietary supplementation
MeSH terms: Resveratrol, Adult, Alanine Transaminase, Anti-Inflammatory Agents, Antioxidants, Blood Pressure, Cardiovascular Diseases, Double-Blind Method, Fatty Liver, Female, Humans, Insulin Resistance, Liver, Male, Phytotherapy, Middle Aged, Plant Extracts, Risk Factors, Stilbenes, Triglycerides, Biomarkers, Dietary Supplements, Lipid Metabolism, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks